



**JOHN WAYNE
CANCER INSTITUTE**
at Providence Saint John's Health Center

For more information, contact
the **Neuro-Oncology
Clinical Trial Team** at:
neuro.oncology@jwci.org
310-829-8265

Clinical Trial Investigators

Achal S. Achrol, MD

Garni Barkhoudarian, MD

Daniel Kelly, MD

Santosh Kesari, MD, PhD,

Steven O'Day, MD

Marlon Garzo Saria, PhD, RN

Clinical Trial Team

Najee Boucher, CRA

najee.boucher@providence.org
310-582-7460

Jaya Gill, RN, BSN

jaya.gill@providence.org
310-582-7437

Annie Heng, RN, BSN

HengA@jwci.org
310-582-7457

Tiffany Juarez, PhD

Tiffany.Juarez@jwci.org
310-449-5225

Anand Moses, CRA

MosesA@jwci.org
310-582-7097

Sponsor

PNI/JWCI

**Saint John's
Health Center**

 **PROVIDENCE** Health & Services

CLINICAL TRIAL ANNOUNCEMENT

A Longitudinal Assessment of Tumor Evolution in Patients with Brain Cancer

This is a randomized, longitudinal assessment of tumor evolution in patients with newly diagnosed glioblastoma. Study is designed to assess the safety and tolerability of administering nivolumab and nivolumab in combination with ipilimumab prior to radiation therapy and to collect biological specimens before, during, and after treatments to identify determinants of response and safety. Parallel assessment of the effect of standard radiation and temozolomide on tumor microenvironment will provide a comparison leading to a deeper understanding of tumor stratification for personalized medicine.

Three treatment arms in the study will include (1) Standard of Care: Radiation + Temozolomide, (2) Nivolumab prior to radiation, and (3) Nivolumab + Ipilimumab prior to radiation.

Nivolumab is a programmed death receptor-1 (PD-1) blocking human monoclonal antibody.

Ipilimumab is a monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and blocks its interaction with various ligands.

Glioblastoma (GBM) being one of the most common malignant central nervous system tumors, remains a disease with a significant unmet medical need. Cancer immunotherapy has recently proven its value in the treatment of many solid and hematological cancers. GBM are known to induce local and systemic immunosuppression and immunotherapy holds promise of specifically targeting and eliminating tumor cells while sparing normal brain.

Key Inclusion Criteria:

- Participant is being evaluated for a potential diagnosis of glioblastoma with pathology confirming diagnosis of glioblastoma.
- Age ≥ 18 .
- KPS score of ≥ 60 .

Key Exclusion Criteria:

- Prior anti-cancer treatment for glioblastoma